Literature DB >> 10655279

Which patients with hepatitis C develop liver complications?

M H Khan1, G C Farrell, K Byth, R Lin, M Weltman, J George, D Samarasinghe, J Kench, S Kaba, E Crewe, C Liddle.   

Abstract

To identify variables that are independent predictors of adverse outcomes in chronic hepatitis C, we analyzed a cohort of 455 patients followed for a median of 4.7 years. Associations were sought between demographic and behavioral factors, hepatitis C virus (HCV) genotype, liver histology and liver tests at entry, and development of liver complications, hepatocellular carcinoma (HCC), hepatic transplantation and liver-related death. Independent predictors were identified by multivariate analysis. The following were associated with a significantly higher rate of liver complications: age; birth in Asia, Europe, Mediterranean region, or Egypt; transmission by blood transfusion or sporadic cases; HCV genotypes 1b and 4 (compared with 1/1a); fibrosis stage 3 or 4 (cirrhosis); serum albumin; bilirubin; prothrombin time; and alpha-fetoprotein. However, the only independent predictors of liver-related complications were sporadic transmission (P <.001), advanced fibrosis (P =.004), and low albumin (P <.001). The corresponding independent risk factors for HCC were male gender (P =. 07), sporadic transmission (P <.001), and albumin (P <.001); bilirubin (P =.02) was an additional predictor of transplantation or liver-related death. It is concluded that only patients with advanced hepatic fibrosis or cirrhosis, are at risk of developing hepatic complications of chronic hepatitis C during 5-year follow-up. Among such patients, abnormalities in serum albumin, bilirubin, or prothrombin time indicate a high probability of complications. Patients without definite risk factors for HCV (sporadic cases) are at higher risk of complications, possibly because of interaction between older age, duration of infection, country of birth, and HCV genotypes 1b and 4.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655279     DOI: 10.1002/hep.510310236

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Prevalence of occult HBV infection in haemodialysis patients with chronic HCV.

Authors:  Vedat Goral; Hamza Ozkul; Selahattin Tekes; Dede Sit; Ali Kemal Kadiroglu
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

2.  Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C.

Authors:  Agostino Colli; Alice Colucci; Silvia Paggi; Mirella Fraquelli; Sara Massironi; Marco Andreoletti; Vittorio Michela; Dario Conte
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 3.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 4.  Impact of new treatment options for hepatitis C virus infection in liver transplantation.

Authors:  Elda Righi; Angela Londero; Alessia Carnelutti; Umberto Baccarani; Matteo Bassetti
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 5.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

6.  Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

Authors:  Robert P Myers; Mercedes De Torres; Françoise Imbert-Bismut; Vlad Ratziu; Frédéric Charlotte; Thierry Poynard
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

7.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Authors:  Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch
Journal:  Virology       Date:  2008-03-17       Impact factor: 3.616

8.  Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

Authors:  Marc G Ghany; Anna S F Lok; James E Everhart; Gregory T Everson; William M Lee; Teresa M Curto; Elizabeth C Wright; Anne M Stoddard; Richard K Sterling; Adrian M Di Bisceglie; Herbert L Bonkovsky; Chihiro Morishima; Timothy R Morgan; Jules L Dienstag
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

9.  Effects of Nigella sativa on outcome of hepatitis C in Egypt.

Authors:  Eman Mahmoud Fathy Barakat; Lamia Mohamed El Wakeel; Radwa Samir Hagag
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

Review 10.  New therapies for chronic hepatitis C virus infection.

Authors:  Anouk Dev; Keyur Patel; John G McHutchison
Journal:  Curr Gastroenterol Rep       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.